Cargando…

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

BACKGROUND: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy. Physiological changes in pregnancy alter the pharmacokinetics of some medications; th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chappell, Catherine A, Scarsi, Kimberly K, Kirby, Brian J, Suri, Vithika, Gaggar, Anuj, Bogen, Debra L, Macio, Ingrid S, Meyn, Leslie A, Bunge, Katherine E, Krans, Elizabeth E, Hillier, Sharon L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491553/ https://www.ncbi.nlm.nih.gov/pubmed/32939459 http://dx.doi.org/10.1016/S2666-5247(20)30062-8

Ejemplares similares

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis
por: He, Qiu-Feng, et al.
Publicado: (2016)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
por: Omotani, Sachiko, et al.
Publicado: (2020)

Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment
por: Golden‐Mason, Lucy, et al.
Publicado: (2018)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial
por: Elgohary, Mohamed Abdel-Salam, et al.
Publicado: (2022)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir
por: Wang, Xiao-Xiao, et al.
Publicado: (2018)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
por: Stokes, William, et al.
Publicado: (2017)

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O’Brien, Thomas R., et al.
Publicado: (2015)

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
por: Palaniswami, Paari M, et al.
Publicado: (2018)

Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2019)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
por: Covini, Giovanni, et al.
Publicado: (2018)

The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2022)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Analysis of Subgroup Differences in the ION-3 Trial of Ledipasvir-Sofosbuvir in Chronic Hepatitis C Infection
por: Kowdley, Kris V., et al.
Publicado: (2015)

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
por: Husson, Jennifer S., et al.
Publicado: (2017)

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
por: Brown, Patrick R., et al.
Publicado: (2018)

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
por: Schwarz, Kathleen B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3531o9jnt67i20i79d8mb3f91n